Meehyun Chun

Meehyun Chun

Auto-generated profile, based on publicly available information

Meehyun Chun

Department of Chemistry Seoul National University Seoul South Korea

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
JLJesang Lee
Jesang Lee
SSSumin Son
Sumin Son
JYJeong Yeon Yoo
Jeong Yeon Yoo
JLJi Hyae Lee
Ji Hyae Lee
MCMeehyun Chun
Meehyun Chun
Seung Bum ParkSeung Bum Park
Seung Bum Park
Peptidomimetics have matured from motif‑based inhibitors into a structural engineering discipline that systematically translates peptide recognition surfaces into drug‑like scaffolds. Driven by the urgent clinical demand to overcome the inherent pharmacological liabilities of biomolecules, the field is undergoing a decisive Peptide‐to‐Small Molecule paradigm shift—functionally converting peptide‐derived recognition motifs into orally bioavailable synthetic therapeutics. This Perspective highlights how foundational geometric design principles—linear repetition, convergent fusion, and cyclization—define next‑generation architectures capable of targeting complex protein–protein interactions (PPIs). Repeating‑unit oligomers exemplify linear projection strategies, heterocycle‑centered scaffolds embody the convergent fusion of recognition motifs, and macrocyclic frameworks pre‐organize bioactive conformations while enabling access to non‑canonical topologies. Beyond simple mimicry, these architectures increasingly embrace dynamic responsiveness, aggregation remodeling, and universal multi‑structure platforms. We argue that the convergence of geometric logic with automated synthesis and AI‑driven design will transform peptidomimetics into a primary modality for decoding and therapeutically engaging the human interactome, including historically “undruggable” PPIs.

11 August 2026 in Angewandte Chemie
Verified
Journal Article
Open access
JLJesang Lee
Jesang Lee
SSSumin Son
Sumin Son
JYJeong Yeon Yoo
Jeong Yeon Yoo
JLJi Hyae Lee
Ji Hyae Lee
MCMeehyun Chun
Meehyun Chun
Seung Bum ParkSeung Bum Park
Seung Bum Park
Peptidomimetics have matured from motif‑based inhibitors into a structural engineering discipline that systematically translates peptide recognition surfaces into drug‑like scaffolds. Driven by the urgent clinical demand to overcome the inherent pharmacological liabilities of biomolecules, the field is undergoing a decisive Peptide‐to‐Small Molecule paradigm shift—functionally converting peptide‐derived recognition motifs into orally bioavailable synthetic therapeutics. This Perspective highlights how foundational geometric design principles—linear repetition, convergent fusion, and cyclization—define next‑generation architectures capable of targeting complex protein–protein interactions (PPIs). Repeating‑unit oligomers exemplify linear projection strategies, heterocycle‑centered scaffolds embody the convergent fusion of recognition motifs, and macrocyclic frameworks pre‐organize bioactive conformations while enabling access to non‑canonical topologies. Beyond simple mimicry, these architectures increasingly embrace dynamic responsiveness, aggregation remodeling, and universal multi‑structure platforms. We argue that the convergence of geometric logic with automated synthesis and AI‑driven design will transform peptidomimetics into a primary modality for decoding and therapeutically engaging the human interactome, including historically “undruggable” PPIs.